KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Current Assets (2017 - 2025)

Bionano Genomics' Current Assets history spans 7 years, with the latest figure at $48.8 million for Q3 2025.

  • For Q3 2025, Current Assets rose 3.87% year-over-year to $48.8 million; the TTM value through Sep 2025 reached $48.8 million, up 3.87%, while the annual FY2024 figure was $39.5 million, 71.82% down from the prior year.
  • Current Assets for Q3 2025 was $48.8 million at Bionano Genomics, up from $42.7 million in the prior quarter.
  • Across five years, Current Assets topped out at $370.3 million in Q1 2021 and bottomed at $39.5 million in Q4 2024.
  • The 5-year median for Current Assets is $140.1 million (2023), against an average of $160.0 million.
  • The largest annual shift saw Current Assets surged 2080.26% in 2021 before it crashed 71.82% in 2024.
  • A 5-year view of Current Assets shows it stood at $272.4 million in 2021, then crashed by 42.26% to $157.3 million in 2022, then fell by 10.92% to $140.1 million in 2023, then plummeted by 71.82% to $39.5 million in 2024, then rose by 23.58% to $48.8 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Current Assets are $48.8 million (Q3 2025), $42.7 million (Q2 2025), and $44.9 million (Q1 2025).